Anthrax
A. Trastuzumab
B. Ofatumumab
C. Raxibacumab
D. Cetuximab
ANSWER-C.
C. Raxibacumab
——————–
Raxibacumab is a human monoclonal antibody used for the prophylaxis and treatment of inhaled anthrax.
A. pXO1 plasmid controls the production of the anthrax edema
B. pXO2 plasmid codes for the capsule
C. pXO1 do not contribute to virulence factors
D. pXO2 plasmid protects the bacteria against phagocytosis
ANSWER-C.
C. pXO1 do not contribute to virulence factors
——————–
The pXO1 plasmid controls the production of the anthrax edema and lethal toxins, which are made of three proteins, the edema factor, the protective antigen, and the lethal factor.
The pXO2 plasmid codes for the capsule, a layer of polysaccharides outside of the cell wall that protects the bacteria against phagocytosis, or consumption by defensive cells from the immune system.
A. Skin
B. Eye
C. Intestine
D. Lungs
ANSWER-B.
B. Eye
——————–
Bacillus anthracis -can occur in four forms: skin, lungs, intestinal, and injection of drugs
A. Skin
B. Eye
C. Intestine
D. Lungs
ANSWER-A.
A. Skin
——————–
Bacillus anthracis -can occur in four forms: skin, lungs, intestinal, and injection of drugs
A. Cutaneous anthrax
B. Injected anthrax
C. Inhalation anthrax
D. Gastrointestinal (GI) infection
ANSWER-A.
A. Cutaneous anthrax
——————–
– Bacillus anthracis -can occur in four forms: skin, lungs, intestinal, and injection of drugs.
– Cutaneous anthrax, also known as hide-porter’s disease, is when anthrax occurs on the skin. It is the most common form (>90% of anthrax cases).
A. Cutaneous anthrax
B. Injected anthrax
C. Inhalation anthrax
D. Gastrointestinal (GI) infection
ANSWER-A.
A. Cutaneous anthrax
——————–
– Cutaneous anthrax – least dangerous form – low mortality with treatment, 23.7% mortality without.
– Cutaneous anthrax – known as hide-porter’s disease, is when anthrax occurs on the skin. It is the most common form (>90% of anthrax cases).
A. Normally do not cause pain
B. Black eschar often shows up
C. Do not forms an ulcer
D. Nearby lymph nodes may become infected
ANSWER-A.
C. Do not forms an ulcer
——————–
Cutaneous anthrax presents as a boil-like skin lesion that eventually forms an ulcer with a black center (eschar)
A. Lethal factor
B. Edema factor
C. Resistance factor
D. Protective antigen
ANSWER-C.
C. Resistance factor
——————–
Anthrax bacilli release three proteins named
– Lethal factor
– Edema factor
– Protective antigen
The three are not toxic by themselves, but their combination is incredibly lethal to humans
A. USA
B. India
C. China
D. France
ANSWER-D.
D. France
——————–
Amerithrax –
2001 anthrax attacks, also known as Amerithrax – occurred in the United States over the course of several weeks beginning on September 18, 2001, one week after the September 11 terrorist attacks.
A. polyribosyl ribitol phosphate (PRP) capsule
B. N-acetyl mannosamine-1-phosphate capsule
C. K1 polysaccharide capsule
D. poly-D-glutamic acid capsule
ANSWER-D.
D. poly-D-glutamic acid capsule
——————–
poly-D-glutamic acid capsule – which protects the bacterium from phagocytosis by host neutrophils
In-Shorts
Inhalational anthrax is also called as ‘woolsorters’ disease’.
Cutaneous anthrax, also known as hide-porter’s disease
